You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

ENTRESTO SPRINKLE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Entresto Sprinkle patents expire, and when can generic versions of Entresto Sprinkle launch?

Entresto Sprinkle is a drug marketed by Novartis and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and twenty-seven patent family members in forty countries.

The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. There are eleven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the sacubitril; valsartan profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Entresto Sprinkle

A generic version of ENTRESTO SPRINKLE was approved as sacubitril; valsartan by ALEMBIC on May 28th, 2024.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ENTRESTO SPRINKLE?
  • What are the global sales for ENTRESTO SPRINKLE?
  • What is Average Wholesale Price for ENTRESTO SPRINKLE?
Summary for ENTRESTO SPRINKLE
Drug patent expirations by year for ENTRESTO SPRINKLE

US Patents and Regulatory Information for ENTRESTO SPRINKLE

ENTRESTO SPRINKLE is protected by four US patents.

Patents protecting ENTRESTO SPRINKLE

Galenic formulations of organic compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF HEART FAILURE WITH ORAL PELLETS

Methods of treatment and pharmaceutical composition
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF HEART FAILURE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis ENTRESTO SPRINKLE sacubitril; valsartan CAPSULE, PELLETS;ORAL 218591-001 Apr 12, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Novartis ENTRESTO SPRINKLE sacubitril; valsartan CAPSULE, PELLETS;ORAL 218591-002 Apr 12, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Novartis ENTRESTO SPRINKLE sacubitril; valsartan CAPSULE, PELLETS;ORAL 218591-001 Apr 12, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Novartis ENTRESTO SPRINKLE sacubitril; valsartan CAPSULE, PELLETS;ORAL 218591-002 Apr 12, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Novartis ENTRESTO SPRINKLE sacubitril; valsartan CAPSULE, PELLETS;ORAL 218591-001 Apr 12, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novartis ENTRESTO SPRINKLE sacubitril; valsartan CAPSULE, PELLETS;ORAL 218591-001 Apr 12, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for ENTRESTO SPRINKLE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Novartis Europharm Limited Neparvis sacubitril, valsartan EMEA/H/C/004343
Paediatric heart failureNeparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5.1).Adult heart failureNeparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1).
Authorised no no no 2016-05-26
Novartis Europharm Limited Entresto sacubitril, valsartan EMEA/H/C/004062
Paediatric heart failureEntresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction.Adult heart failureEntresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.
Authorised no no no 2015-11-19
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ENTRESTO SPRINKLE

When does loss-of-exclusivity occur for ENTRESTO SPRINKLE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 7882
Patent: COMPUESTOS DE ACCION DOBLE DE BLOQUEADORES DEL RECEPTOR DE ANGIOTENSINA E INHIBIDORES DE ENDOPEPTIDASA NEUTRA
Estimated Expiration: ⤷  Sign Up

Patent: 6613
Patent: [HEMI-PENTAHIDRATO DE [3-((1S,3R)-1-BIFENIL-4-ILMETIL-3-ETOXI-CARBONIL-1-BUTIL-CARBAMOIL)-PROPIONATO-(S)-3 -METIL-2 -(PENTANOIL-{2 -(TETRAZOL-5-ILATO)-BIFENIL-4 -ILMETIL}-AMINO)-BUTIRATO] DE TRISODIO
Estimated Expiration: ⤷  Sign Up

Patent: 6614
Patent: COMPUESTOS ORGÁNICOS
Estimated Expiration: ⤷  Sign Up

Australia

Patent: 06311481
Patent: Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 0605921
Patent: compostos orgánicos
Estimated Expiration: ⤷  Sign Up

Patent: 2013025375
Patent: compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 90511
Patent: COMBINAISON PHARMACEUTIQUES D'UN ANTAGONISTE DE RECEPTEUR D'ANGIOTENSINE ET D'UN INHIBITEUR DE NEP (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR)
Estimated Expiration: ⤷  Sign Up

China

Patent: 1098689
Patent: Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor
Estimated Expiration: ⤷  Sign Up

Patent: 2702119
Patent: Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0140274
Estimated Expiration: ⤷  Sign Up

Patent: 0201605
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 15004
Estimated Expiration: ⤷  Sign Up

Patent: 23531
Estimated Expiration: ⤷  Sign Up

Patent: 16014
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 48158
Estimated Expiration: ⤷  Sign Up

Patent: 40828
Estimated Expiration: ⤷  Sign Up

Ecuador

Patent: 14019136
Patent: COMBINACIONES FARMACÉUTICAS DE UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA Y UN INHIBIDOR DE ENDOPEPTIDASA NEUTRA (NEP)
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 48158
Patent: COMBINAISON PHARMACEUTIQUES D'UN ANTAGONISTE DE RECEPTEUR D'ANGIOTENSINE ET D'UN INHIBITEUR DE NEP (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR)
Estimated Expiration: ⤷  Sign Up

Patent: 40828
Patent: Combinaisons pharmaceutiques d'un antagoniste de récepteur de l'angiotensine et inhibiteurs de nep (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR)
Estimated Expiration: ⤷  Sign Up

Patent: 85833
Patent: COMPOSÉ COMPRENANT UN ARB ET UN NEPI (COMPOUND COMPRISING AN ARB AND A NEPI)
Estimated Expiration: ⤷  Sign Up

France

Patent: C0018
Estimated Expiration: ⤷  Sign Up

Patent: C1000
Estimated Expiration: ⤷  Sign Up

Guatemala

Patent: 0700055
Patent: COMBINACIONES FARMACEUTICAS DE UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA Y UN INHIBIDOR DE ENDOPEPTIDASA NEUTRAL (NEP).
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 21371
Patent: PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR
Estimated Expiration: ⤷  Sign Up

Patent: 75465
Patent: 血管緊張素受體拮抗劑和 抑制劑的藥物組合產品 (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR NEP)
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 50870
Estimated Expiration: ⤷  Sign Up

Patent: 600025
Estimated Expiration: ⤷  Sign Up

Patent: 100003
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 4027
Patent: תרכובת טריסודיום [3-((1s, 3r)-1-ביפניל-4-ילמתיל-3-אתוקסיקרבוניל-1-בוטילקרבמויל)פרופיונאט-(s)-'3-מתיל-'2-(פנטהנויל{" 2-(טטרזול-5-ילאט)ביפניל-'4-ילמתיל}אמינו)בוטיראט] המיפנטההידראט, תכשירים רוקחיים שלה, שיטה להכנתה ושימוש בה להכנת תרופות (Compound trisodium [3-((1s,3r)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(s)-3’-methyl-2’-(pentanoyl{2’’-(tetrazol-5-ylate)biphenyl-4’-ylmethyl}amino)butyrate] hemipentahydrate, its pharmaceutical compositions, method for its preparation and use thereof in the preparation of medicaments)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 24754
Estimated Expiration: ⤷  Sign Up

Patent: 08542447
Estimated Expiration: ⤷  Sign Up

Patent: 11252013
Patent: PHARMACEUTICAL COMBINATION OF ANGIOTENSIN RECEPTOR ANTAGONIST AND NEP INHIBITOR
Estimated Expiration: ⤷  Sign Up

Patent: 15098485
Patent: アンギオテンシン受容体遮断剤とNEP阻害剤との医薬組成物 (PHARMACEUTICAL COMBINATIONS OF ANGIOTENSIN RECEPTOR ANTAGONIST AND NEP INHIBITOR)
Estimated Expiration: ⤷  Sign Up

Jordan

Patent: 92
Patent: تركيبات صيدلانية من مضاد مستقبل أنجيوتنسين ومثبط NEP (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR)
Estimated Expiration: ⤷  Sign Up

Lithuania

Patent: 948158
Estimated Expiration: ⤷  Sign Up

Patent: 2021502
Estimated Expiration: ⤷  Sign Up

Patent: 40828
Estimated Expiration: ⤷  Sign Up

Malaysia

Patent: 5462
Patent: PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 07008075
Patent: COMBINACIONES FARMACEUTICAS DE UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA Y UN INHIBIDOR DE ENDOPEPTIDASA NEUTRAL (NEP). (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR.)
Estimated Expiration: ⤷  Sign Up

Morocco

Patent: 128
Patent: COMBINAISONS PHARMACEUTIQUES D'UN ANTAGONISTE DE RECEPTUER D'ANGIOTENSINE ET D'UN INHIBITEUR DE NEP
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 4006
Patent: Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor
Estimated Expiration: ⤷  Sign Up

Patent: 0626
Patent: Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor
Estimated Expiration: ⤷  Sign Up

Norway

Patent: 7288
Estimated Expiration: ⤷  Sign Up

Patent: 0315
Estimated Expiration: ⤷  Sign Up

Patent: 16008
Estimated Expiration: ⤷  Sign Up

Patent: 073396
Estimated Expiration: ⤷  Sign Up

Patent: 151656
Patent: Farmasøytiske kombinasjoner av en angiotensinreseptorantagonist og en nepinhibitor
Estimated Expiration: ⤷  Sign Up

Peru

Patent: 070803
Patent: COMBINACION FARMACEUTICA DE UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA Y UN INHIBIDOR DE ENDOPEPTIDASA NEUTRA
Estimated Expiration: ⤷  Sign Up

Patent: 190374
Patent: COMBINACION FARMACEUTICA DE UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA Y UN INHIBIDOR DE ENDOPEPTIDASA NEUTRA
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 48158
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 48158
Estimated Expiration: ⤷  Sign Up

Patent: 40828
Estimated Expiration: ⤷  Sign Up

Russian Federation

Patent: 59809
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ АНТАГОНИСТА РЕЦЕПТОРА АНГИОТЕНЗИНА И ИНГИБИТОРА NEP (PHARMACEUTICAL COMBINATIONS OF ANGIOTENSINE RECEPTOR ANTAGONIST AND NEP INHIBITOR)
Estimated Expiration: ⤷  Sign Up

Patent: 03668
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ АНТАГОНИСТА РЕЦЕПТОРА АНГИОТЕНЗИНА И ИНГИБИТОРА NEP (PHARMACEUTICAL COMBINATIONS OF ANGIOTENSIN RECEPTOR ANTAGONIST AND NEP INHIBITOR)
Estimated Expiration: ⤷  Sign Up

Patent: 07123671
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ АНТАГОНИСТА РЕЦЕПТОРА АНГИОИЕНЗИНА И ИНГИБИТОРА NEP
Estimated Expiration: ⤷  Sign Up

Patent: 12107219
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ АНТАГОНИСТА РЕЦЕПТОРА АНГИОТЕНЗИНА И ИНГИБИТОРА NEP
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 201402055Y
Patent: PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 48158
Estimated Expiration: ⤷  Sign Up

Patent: 40828
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 0704717
Patent: Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 1432821
Estimated Expiration: ⤷  Sign Up

Patent: 1549318
Estimated Expiration: ⤷  Sign Up

Patent: 080075055
Patent: PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR
Estimated Expiration: ⤷  Sign Up

Patent: 130116381
Patent: PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 49765
Estimated Expiration: ⤷  Sign Up

Patent: 23749
Estimated Expiration: ⤷  Sign Up

Taiwan

Patent: 18348
Estimated Expiration: ⤷  Sign Up

Patent: 54504
Estimated Expiration: ⤷  Sign Up

Patent: 0803834
Patent: Organic compounds
Estimated Expiration: ⤷  Sign Up

Patent: 1402111
Patent: Dual-acting compound, pharmaceutical composition containing it, process for its preparation and use thereof
Estimated Expiration: ⤷  Sign Up

Tunisia

Patent: 07264
Patent: ORGANIC COMPOUNDS
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ENTRESTO SPRINKLE around the world.

Country Patent Number Title Estimated Expiration
Hungary S2100003 ⤷  Sign Up
Slovenia 2340828 ⤷  Sign Up
China 1615134 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 03059345 ⤷  Sign Up
Norway 20043380 ⤷  Sign Up
Morocco 30128 COMBINAISONS PHARMACEUTIQUES D'UN ANTAGONISTE DE RECEPTUER D'ANGIOTENSINE ET D'UN INHIBITEUR DE NEP ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ENTRESTO SPRINKLE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2340828 2021C/502 Belgium ⤷  Sign Up PRODUCT NAME: SACUBITRIL/VALSARTAN, ALS HET SACUBITRIL VALSARTAN NATRIUMZOUTCOMPLEX, I.E. (((S)-N-VALERYL-N-((2'-(1H-TETRAZOL-5-YL)-BIFENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIFENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTAANZUURETHYLESTER))NA3 . X H2O, WAARBIJ X 0 TOT 3 IS; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 (C(2015) 8288) 20151123
1948158 1690020-1 Sweden ⤷  Sign Up PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
1467728 C01467728/01 Switzerland ⤷  Sign Up PRODUCT NAME: SACUBRITIL UND VALSARTAN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65673 17.09.2015
1948158 300810 Netherlands ⤷  Sign Up PRODUCT NAME: SACUBITRIL/VALSARTAN, ALS HET SACUBITRIL VALSARTAN NATRIUMZOUTCOMPLEX, IE. TRINATRIUM (3-((LS,3R)-1-BIFENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONAAT-(S)-3'-METHYL-2'-(PENTANOYL(2"-(TETRAZOL-5-YLAAT)BIFENYL-4'-YLMETHYL)AMINO)BUTYRAAT) HEMIPENTAHYDRAAT; REGISTRATION NO/DATE: EU/1/15/1058 20151123
1467728 340 5007-2016 Slovakia ⤷  Sign Up PRODUCT NAME: SAKUBITRIL/VALSARTAN, VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/15/1058 20151123
1467728 16C0019 France ⤷  Sign Up PRODUCT NAME: SACUBITRIL/VALSARTAN,Y COMPRIS LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/1058 20151123
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.